Gene therapy and tissue engineering for urologic dysfunction: status and prospects.
This article reviews the recent advances in gene therapy and tissue engineering for urologic dysfunction. Although the number of gene therapy-based clinical trials has increased dramatically in the field of urologic oncology, such trials are still few within the neurourologic field. Recently, new biologic approaches employing growth factors have been utilized to treat various pathological conditions. Among them, transfer of genes such as those encoding growth factors represents a promising way to deliver therapeutic proteins to malfunctioning tissues, which leads to the improvement of organ function. Tissue engineering, which may eventually be combined with gene therapy, also offers the potential to create new functional genitourinary tissue for regeneration and replacement of tissue lost as a consequence of disease. Thus, both tissue engineering and gene therapy may hold promising new solutions in the urologic field.
Yokoyama
T
T
Department of Urology, Okayama Graduate School of Medicine and Dentistry, Okayama, Japan. uroyoko@hospital.okayama.u.ac.jp
Chancellor
M B
MB
Yoshimura
N
N
Huard
J
J
Kumon
H
H
D000818:Animals; D017690:Cell Transplantation; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D023822:Tissue Engineering / Q000379:methods*; D001743:Urinary Bladder / Q000473:pathology; D014570:Urologic Diseases / Q000628:therapy*